Literature DB >> 18236211

The antibody sc-33040-R fails to specifically recognize phosphorylation of ErbB4 on tyrosine1056.

Richard M Gallo1, David J Riese.   

Abstract

Phosphorylation state specific antibodies are important reagents for characterizing protein phosphorylation and signaling. However, these antibodies require proper validation to determine that they do not cross-react with the unphosphorylated peptide or with other phosphoproteins. We have previously shown that phosphorylation of tyrosine1056 of ErbB4 is critical for it to inhibit colony formation on plastic by human tumor cell lines. Thus, an antibody directed against this site would be useful for studying ErbB4 signaling and coupling to biological responses. Here, we demonstrate that a commercially available antibody raised against a phosphopeptide corresponding to the carboxyl-terminal domain of the ErbB4 receptor tyrosine kinase fails to exhibit appropriate specificity. Thus, this antibody does not appear to be suitable for studying ErbB4 phosphorylation or signaling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18236211      PMCID: PMC2435050          DOI: 10.1080/08977190701804008

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  39 in total

1.  Ligand discrimination in signaling through an ErbB4 receptor homodimer.

Authors:  C Sweeney; C Lai; D J Riese; A J Diamonti; L C Cantley; K L Carraway
Journal:  J Biol Chem       Date:  2000-06-30       Impact factor: 5.157

2.  Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation.

Authors:  Stuart S Hobbs; Stephanie L Coffing; Ann T D Le; Elizabeth M Cameron; Eric E Williams; Michelle Andrew; Erika N Blommel; Robert P Hammer; Han Chang; David J Riese
Journal:  Oncogene       Date:  2002-12-05       Impact factor: 9.867

3.  EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival.

Authors:  Zhenhe Suo; Bjørn Risberg; Mats G Kalsson; Kenneth Willman; Anne Tierens; Eva Skovlund; Jahn M Nesland
Journal:  J Pathol       Date:  2002-01       Impact factor: 7.996

Review 4.  Untangling the ErbB signalling network.

Authors:  Y Yarden; M X Sliwkowski
Journal:  Nat Rev Mol Cell Biol       Date:  2001-02       Impact factor: 94.444

5.  Multisite phosphotyping of the ErbB-2 oncoprotein in human breast cancer.

Authors:  X Ouyang; T Gulliford; G C Huang; C Harper-Wynne; S Shousha; R J Epstein
Journal:  Mol Diagn       Date:  2001-03

6.  Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer.

Authors:  A D Thor; S Liu; S Edgerton; D Moore; K M Kasowitz; C C Benz; D F Stern; M P DiGiovanna
Journal:  J Clin Oncol       Date:  2000-09-15       Impact factor: 44.544

Review 7.  Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants.

Authors:  T T Junttila; M Sundvall; J A Määttä; K Elenius
Journal:  Trends Cardiovasc Med       Date:  2000-10       Impact factor: 6.677

8.  Constitutively active ErbB4 and ErbB2 mutants exhibit distinct biological activities.

Authors:  Desi J Penington; Ianthe Bryant; David J Riese
Journal:  Cell Growth Differ       Date:  2002-06

9.  A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines.

Authors:  Eric E Williams; Laurie J Trout; Richard M Gallo; Sarah E Pitfield; Ianthe Bryant; Desi J Penington; David J Riese
Journal:  Cancer Lett       Date:  2003-03-20       Impact factor: 8.679

10.  c-erbB-4 protein expression in human breast cancer.

Authors:  T Y Kew; J A Bell; S E Pinder; H Denley; R Srinivasan; W J Gullick; R I Nicholson; R W Blamey; I O Ellis
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

View more
  3 in total

1.  The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist.

Authors:  Kristy J Wilson; Christopher P Mill; Richard M Gallo; Elizabeth M Cameron; Henry VanBrocklin; Jeffrey Settleman; David J Riese
Journal:  Biochem J       Date:  2012-04-01       Impact factor: 3.857

Review 2.  ErbB4 in the brain: Focus on high grade glioma.

Authors:  Jamie-Lee Pitcher; Naomi Alexander; Panimaya Jeffreena Miranda; Terrance G Johns
Journal:  Front Oncol       Date:  2022-08-31       Impact factor: 5.738

3.  Convergent and divergent cellular responses by ErbB4 isoforms in mammary epithelial cells.

Authors:  Vikram B Wali; Jonathan W Haskins; Maureen Gilmore-Hebert; James T Platt; Zongzhi Liu; David F Stern
Journal:  Mol Cancer Res       Date:  2014-05-14       Impact factor: 6.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.